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Introduction:
Estrogen controls several biological processes by functioning as a ligand for nuclear receptors estrogen receptor alpha (ERα) and beta (ERβ) (1). ERs may participate in the genomic (transcriptional) and non-genomic actions of estrogen (1, 2). The genomic action involves binding of ERα to the regulatory regions of target genes either directly or through protein-protein interaction. DNA-bound ERα then recruits various co-regulatory molecules to induce chromatin modifications to either increase or decrease the levels of target gene transcripts. Several extracellular signal activated kinases phosphorylate and modulate ERα activity. The major kinases that modulate ERα activity include ERK1/2, AKT, RSK, PAK1, p38 kinase and SRC (2) (3) (4) . These kinases may alter estrogen response and confer resistance to anti-estrogen therapy in breast cancer (2) .
A significant number of studies so far have focused on estrogen:ERα-mediated transcriptome. The effect of estrogen on gene expression at post-transcriptional level, particularly by recently discovered microRNAs, is yet to be elucidated. MicroRNAs are a class of evolutionarily conserved non-coding RNAs that control gene expression at posttranscriptional level (5, 6) . They regulate gene expression through direct cleavage of the target mRNAs or inhibiting translation through eIF6 upon binding to target sequences in the 3' untranslated region of transcripts (5, 7) . However, control of gene expression at the level of translation by microRNA is cell cycle dependent (8) . Each microRNA is predicted to target 90-300 mRNA species and together affect ~30% of the protein coding genes (9) . Cellular stress and RNA binding proteins, which usually bind to sequences in between microRNA recognition sites on mRNAs, determine the target specificity of microRNAs (10, 11) . The additional functions of microRNAs include transcriptional activation of genes with complementary promoter sequences (12) and chromatin modification (13, 14) .
The majority of microRNAs are transcribed by the RNA pol II enzyme (a minority by pol III) to produce a primary-microRNA (15, 16) . Approximately 50% of microRNAs are transcribed from introns of protein coding genes while the rest are intergenic with primary transcripts as long as 4 kb (16) . The primary-microRNA form specific hairpin-shaped stem-loop structure, enter a microprocessor complex and then processed to 60-to-70-nt pre-miRNA. These pre-miRNAs are further processed to a short microRNA in the cytoplasm and incorporated into RNA-induced silencing complex (RISC) where they regulate translation or stability of their target mRNAs. The processing of the microRNAs is under additional control by RNA binding proteins such as LIN28 (17) .
The miRNA genes usually appear in polycistronic clusters and more than 50% of miRNA genes are located in cancer associated genomic regions of fragile sites (5, 18) . Thus, because of their enormous influence on expression of multiple genes, an alteration in the expression of a single microRNA can have profound effect on cellular physiology. Indeed, specific reduction or upregulation of microRNAs is observed in cancers. For example, RAS oncogene is frequently activated/mutated in cancers (19) . Translation of RAS is controlled by Let-7 microRNA whose expression is often reduced in cancers (20, 21) . In general, it is believed that Let-7/miR-98 family microRNAs prevent the reexpression of oncofetal genes in adult tissues and loss of their expression leads to reexpression of oncofetal genes in cancer (22, 23) . In contrast, miR-17-92 cluster is overexpressed in lung cancer and these microRNAs induce tumor growth possibly by targeting tumor suppressors PTEN and Rb2 (24) . Glioblastomas show upregulation of miR-221 whereas testicular cancers overexpress miR-372 and miR-373 (24, 25) .
Three recent reports describe microRNA expression pattern in breast cancer; two of these have evaluated the expression pattern in relation to ERα, ErbB2 and intrinsic subtypes (26) (27) (28) . Overall, microRNA levels were lower in poorly differentiated tumors compared to well-differentiated tumors. MicroRNA profile rather than mRNA expression profile correlated more accurately with cell differentiation. Expression of Let-7 family microRNAs was lower in ErbB2-positive breast cancers compared to other cancer types. ErbB2-positive breast cancers overexpressed 43 microRNAs compared to ErbB2-negative breast cancers. Similarly, 43 microRNAs were expressed at higher level in ERα-positive breast cancers compared to ER-negative breast cancers (26) . Blenkiron et al., described microRNA expression profile in relation to intrinsic subtypes of breast cancer (27) . Breast cancers have been classified to five distinct subtypes (luminal subtypes A and B, Her-2+/ER-, basal-like, and normal-like subtypes) based on gene expression pattern with unique molecular characteristics and prognostic significance (29, 30) . Luminal subtype A and B correspond to ERα-positive breast cancers with subtype A expressing higher levels of ERα and having a better prognosis than subtype B (30) . ERα expression in breast cancer may be regulated by microRNAs as estrogen increases miR-206 expression, which in turn inhibits ERα translation by binding to 3' UTR of ERα mRNA (31) . Luminal type A and basal type breast cancers displayed distinct pattern of microRNA expression (27) . The ErbB2-positive tumors shared many of the microRNAs with basal tumors with the exception of miR-106a, miR-18a, miR-93, miR-155 and miR135b, which were expressed at lower levels than in basal cancer types (27) .
Despite enormous progress in understanding the expression pattern of microRNA in breast cancer, regulation of their expression in different breast cancer subtypes is not known. We focused on the effect of estrogen on microRNA expression in breast cancer cells with two goals. One was to determine whether any of the microRNAs expressed at higher levels in luminal type A/ ERα-positive breast cancer are regulated by estrogen. The second was to determine whether genes that are regulated by estrogen at transcription levels are subsequently controlled by estrogen-regulated microRNAs. We also examined whether extracellular signal activated kinases such as AKT modulate estrogen regulated microRNA expression. Results from this study revel a unique role for estrogen in regulating the expression of luminal type A-enriched microRNAs with tumor suppressor and oncogenic functions and the influence of AKT in altering the effects of estrogen.
Body:
Objectives: 1) Determine estrogen-regulated expression of microRNAs in MCF-7 cells using microRNA bioarrays and investigate their role in estrogen-mediated repression of genes and proliferation. 2) Investigate whether microRNAs induced by c-Myc are involved in estrogen-mediated repression of genes.
Progress on Objectives 1 and 2: Estrogen regulates the expression of microRNAs
Our ongoing studies with parental MCF-7 cells with retrovirus vector alone (MCF-7pQXIP) and MCF-7 cells overexpressing constitutively active AKT (MCF-7/CA-AKT) revealed 1667 and 1908 genes, respectively, bound to ERα upon estrogen treatment (manuscript under revision). However, not all of the genes with ERα binding sites had an altered transcript level after estrogen treatment. Also, not all estrogenregulated genes, as identified by microarray analysis of both cell types with or without estrogen treatment for four hours, contained ERα binding sites suggesting that there are other mechanisms by which estrogen regulates gene expression. In fact, among 833 estrogen-regulated genes in MCF-7pQXIP cells, only 299 genes contained ERα binding sites. Although secondary estrogen response through estrogen regulated transcription factors such as E2F1/2 can explain the lack of correlation between ERα binding and target gene expression (32) , control of gene expression by estrogen-regulated microRNAs has not been investigated so far. To investigate this possibility, we determined microRNA expression pattern in MCF-7pQXIP and MCF-7CA-AKT cells with or without estrogen treatment for four hours as detailed below.
MicroRNA microarray consisted 248 human microRNAs. With a statistical cutoff p value <0.05 and fold change >1.5 or <0.7, we observed 21 estrogen-inducible and seven estrogen-repressible microRNAs in MCF-7pQXIP cells (Table 1) . Estrogen increased the expression of eight members of Let-7 family (≥ 2.2 fold increase), which are abundantly expressed in luminal type A breast cancer (27) . AKT completely changed the pattern of estrogen regulation of microRNA expression. In MCF-7CA-AKT cells, estrogen increased the expression of only one microRNA but reduced the expression of 20 microRNA species. Basal expression of 11 microRNAs was lower in MCF-7CA-AKT cells compared to MCF-7pQXIP cells whereas one microRNA displayed elevated expression in MCF-7CA-AKT cells. Seven of the microRNA that displayed lower basal expression in MCF-7CA-AKT cells were estrogen-inducible in MCF-7pQXIP cells. Only three microRNAs (miR-143, miR-506 and miR-98) showed similar estrogen-dependent regulation in both cell types.
We performed microRNA-qPCR that quantitatively measures only mature microRNAs to confirm estrogen-inducible expression of Let7f, miR-21 and miR-98 ( Figure 1A ). Consistent with results of microarray, estrogen increased the expression of these microRNAs in MCF-7pQXIP cells, which was substantially lower, yet estrogeninducible, in MCF-7/CA-AKT cells. miR-98 was induced by 14-fold whereas Let-7f and miR-21 were induced by ~five-fold in MCF-7pQXIP cells by four hours and dropped to basal level by 24 hours. Estrogen inducible expression of Let-7f, miR-21 and miR-98 was also observed in two other ERα-positive cell lines T47-D and BT-474 ( Figure 1B ).
Kinetics of induction in T47-D, which is a luminal type A cell line, mirrored to that of MCF-7 cells. In contrast, estrogen-inducible expression of these microRNAs was observed at much earlier time point in BT-474 cells, which represents luminal type B (ERα+/HER2+.
Putative targets of estrogen-regulated microRNAs
Estrogen-inducible expression of Let-7 family and reduced basal and estrogeninducible expression of this family members in MCF-7CA-AKT is interesting because reduced expression of this family is linked to loss of differentiation and increased selfrenewal of progenitor cells (33, 34) . Both Let-7 family and miR-98 have the same seed sequence and target same mRNAs. Ras family oncogenes and HMGA2 are the wellcharacterized targets of 35) . By targeting Ras, Let-7 reduces self-renewal whereas by reducing HMGA2, it enhances differentiation without effecting rate of proliferation (36) . c-Myc is also a target of Let-7 (37) and miR-21 (38) . E2F1 and E2F2, two estrogen-inducible transcription factors involved in secondary estrogen response (32) , contain non-conserved Let-7 interaction sites. NCOA3/AIB1 is a target of miR-17-5p (39) , which in our studies is an estrogen-inducible microRNA (Table 1) . EZH2 is a multifunctional protein that integrates Wnt and estrogen signaling in breast cancer cells and the abnormal function of this protein is linked to several diseases (40) . EZH2 is subject to post-transcriptional regulation by miR-26a in myotubes (41) . Based on TargetScan analysis, EZH2 is a likely target of mir-124a and mir-506, both of which are repressed by estrogen. By repressing the levels of these microRNAs, estrogen can cause an increase in EZH2 protein. The above genes thus constituted potential targets of estrogen-regulated microRNAs.
We confirmed estrogen-mediated repression of Ras protein in MCF-7pQXIP cells, which was not observed in MCF-7CA-AKT cells (Figure 2A ). We observed repression of AIB1 and induction of EZH2 by estrogen in both cell types. Additionally, while E2F1 and E2F2 displayed delayed E2-inducible increase in protein levels in MCF7pQXIP cells, basal levels of both of these proteins were elevated with further estrogen inducible increase in MCF-7CA-AKT cells. Previously, we reported little difference in the kinetics of estrogen-induced increase in c-Myc mRNA levels in parental and CA-AKT overexpressing MCF-7 cells (3). However, estrogen-induced increase in c-Myc proteins is advanced in MCF-7CA-AKT cells compared to MCF-7pQXIP cells ( Figure  2A) . None of the previous microarray profiling studies including our study observed an effect of estrogen on EZH2 and Ras mRNA levels and our ChIP-chip data did not identify ERα binding sites in these genes. We believe that estrogen changes levels of Ras, AIB1 and EZH2 through microRNA-mediated post-transcriptional mechanisms.
The effect of Let-7f/miR-98 and miR-21 knockdown on estrogen-induced levels of cMyc, E2F1 and E2F2 proteins
We used locked nucleic acid (LNA) mediated knockdown of Let-7f/miR98 to determine whether reducing the levels of these microRNA leads to changes in the estrogen-inducible expression of c-Myc, E2F1, and E2F2 at protein level. Neither LNA against Let-7f/miR-98 nor LNA against miR-21 had any effect on estrogen-inducible expression of E2F1 ( Figure 2B ). Basal level of E2F2 was substantially higher in miR-21 LNA treated MCF-7pQXIP cells compared to control LNA-treated cells, which was further increased by estrogen. LNA against Let-7f/miR-98 but not miR-21 increased the basal levels of c-Myc proteins. LNA against Let-7f or miR-98 individually was ineffective, possibly due to their redundant targets. Estrogen mediated reduction of AIB1 protein levels was unaffected by LNA against Let-7f/miR-98 or miR-21 ( Figure 2B ). We were unable to observe an effect of LNA against Let-7f/miR-98 on Ras protein levels possibly due to the effects of other estrogen-induced Let-7 family members on translation of Ras (data not shown). Also, due to undetectable levels of HMGA2 protein in MCF-7 cells, the effect of estrogen on this protein could not be evaluated (data not shown).
Bioinformatics analysis of potential targets of estrogen-regulated microRNAs identify additional estrogen-responsive genes
We next determined whether any of the estrogen-regulated genes are the targets of estrogen-regulated microRNAs. To facilitate this analysis, we first identified estrogeninducible and estrogen-repressed genes in MCF-7pQXIP and MCF-7CA-AKT cells by microarray analysis of untreated and four-hour estrogen treated cells. These estrogenregulated as well as non-estrogen regulated genes were then scanned for microRNA seed sequences. The 21 estrogen-induced microRNAs in MCF7pQXIP cells belong to 10 distinct microRNA families. These microRNAs may target 94 estrogen-inducible, 142 estrogen-repressible and 541 non-estrogen regulated genes in MCF-7pQXIP cells. Detailed statistical analysis is presented in Table 2 . Similar analysis as above was performed with microRNAs repressed by estrogen. Four estrogen-repressed microRNA families, which included 5 repressed microRNAs, potentially target 67 estrogen-inducible, 116 estrogen-repressible, and 407 non-estrogen target genes in MCF-7pQXIP cells ( Table 2 ). Note that has-miR-302b* and has-miR-524* were excluded from this analysis due to the lack of prediction from TargetScan. All together, estrogen-regulated microRNAs target 1021 genes in MCF-7pQXIP cells.
Similar analysis in MCF-7CA-AKT cells showed that estrogen-inducible microRNAs may target 20 estrogen-inducible genes, 20 estrogen-repressed genes and 68 non-estrogen-regulated genes. MicroRNAs repressed by estrogen in these cells may target 148 estrogen-inducible genes, 111 estrogen-repressed genes and 554 non-estrogen target genes (Table 2) . Together, estrogen-regulated microRNAs potentially control 850 genes in MCF-7CA-AKT cells.
Estrogen reduces number of breast cancer progenitor cells as defined by ALDH1-positivity.
We initially developed MCF-7 cells overexpressing Let-7f, miR-21 or miR-98. Although we were able to obtain cells overexpressing these microRNAs (10-2000 fold higher expression levels than control), these cells behaved similar to parental cells with respect to proliferation and some of the target gene expression. These results suggested that microRNA overexpression alone is not sufficient for reduction of target genes or to have a biological effect. Additional parameters such as proteins that target microRNAs for their targets may be essential to see the effect of overexpressed microRNAs. These negative results prompted to us conduct studies described below.
Alcohol dehydrogenase 1 (ALDH1)-positive but not the previously defined CD44+/CD24-phenotype has been suggested to identify tumorigenic progenitor cells of the breast (42) . Also, ALDH1-positive cells from the normal mammary gland have been shown to represent progenitor cells (34) . These progenitor cells express very little Let-7 and the Let-7 level increases upon differentiation. Let-7 overexpression also promotes differentiation of these cells to ALDH1-negative phenotype. Another study described that breast cancer "tumor initiating cells", as defined by CD44+/CD24-phenotype, express lower level of Let-7 and forced expression of Let-7 leads to differentiation (36) . MiR-21, although generally considered as oncogenic, induces differentiation of embryonic stem cells by reducing the levels of c-Myc, Oct-4, Nanog and Sox2 (38) . These results suggest a potential role for estrogen-inducible microRNAs in differentiation of normal or cancerous progenitor cells.
We examined whether estrogen-induced Let-7 and miR-21 microRNAs reduces the number of ALDH1-positive subpopulation of MCF-7 cells. Consistent with this possibility, estrogen treatment reduced the number of ALDH1-positive MCF-7pQXIP and MCF-7CA-AKT cells (Figure 3 ). ALDH1-positive subpopulation of MCF-7 cells could only be detected when cells were maintained in dextran-charcoal treated serum containing media but not in regular serum containing media, which has sufficient estrogen to activate ERα. Despite lower level of estrogen-inducible expression of Let-7f, miR-98 and miR-21, estrogen still reduced ALDH1-positive subpopulation in MCF-7CA-AKT cells indicating that that residual estrogen-mediated induction of Let-7 or some other microRNAs compensate to induce differentiation of these cells. As we reported previously with parental MCF-7 cells (43), MCF-7pQXIP and MCF-7CA-AKT cells were of CD44-/CD24+ phenotype. Therefore, the effect of estrogen-induced Let-7s on differentiation of CD44+/CD24-cells could not be evaluated. In fact, none of ERα-positive cell lines that we have examined contain CD44+/CD24-subpopulation (data not shown). Our repeated attempts to delineate the role of Let-7f, miR-98 and miR-21 in estrogen-induced loss of ALDH1-positive subpopulation using LNA-mediated knockdown did not give interpretable results possibly due to redundant function of other estrogen-induced microRNAs in differentiation of ALDH1-positive cells.
MiR-21 regulatory region contain ERα binding site.
We used our ChIP-on-chip data set and other bioinformatics tools to investigate how estrogen regulates the expression of microRNAs. MicroRNAs can be transcribed as independent units or be a part of intronic sequences of a large transcribed gene (16) . The microRNAs that reside in the intergenic sequence are transcribed as 3-5kb transcripts with clearly defined 5' and 3' boundaries. The promoter/enhancer regions of such microRNA genes are enriched for five transcription factors binding sites: MSX-1, TLX2 (Hox11L1), CDC5, SRF and ZNF238 (16) . Table 3 provides summary of estrogenregulated microRNAs that contain ERα binding sites in their regulatory region or located in the intronic region of known estrogen-regulated genes. We further evaluated ERα binding to miR-21 regulatory region by ChIP assay. Location of miR-21 transcribed region in relation to ERα binding site and the ChIP assay confirming ERα binding are shown in Figure 4 . Unliganded ERα bound to three regions in MCF-7pQXIP cells ( Figure 4A ). Estrogen reduced the number of binding sites to one. ChIP assay was used to confirm ERα binding to the region II (central region). Unliganded ERα binding to this region was observed in MCF-7pQXIP cells (10-fold higher levels of PCR product compared to IgG control), which was reduced modestly upon estrogen treatment. However, ERα binding to this region was observed only in the presence of estrogen in MCF-7CA-AKT cells and total ERα binding to this region with or without estrogen was substantially lower than in MCF-7pQXIP cells. Thus, extracellular signals as well as estrogen control ERα binding to the regulatory regions of miR-21. In summation, our studies reveal the mechanism by which estrogen changes expression pattern of microRNAs and consequences of these changes on the post-transcriptional control of gene expression. Figure 5 shows our current model of how estrogen-regulated microRNAs may control breast cancer progression. We propose that signaling pathways that change the balance between estrogen-regulated tumor suppressor and oncogenic microRNAs dictate estrogen response, differentiation, and progression of the disease. 
Key Research Accomplishments

Conclusions:
